Stryker (SYK) Set to Announce Earnings on Thursday
Stryker (NYSE:SYK) is set to release its earnings data after the market closes on Thursday, October 25th. Analysts expect Stryker to post earnings of $1.68 per share for the quarter. Stryker has set its Q3 guidance at $1.65-1.70 EPS and its FY18 guidance at $7.22-7.27 EPS.
Stryker (NYSE:SYK) last announced its earnings results on Tuesday, July 24th. The medical technology company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.73 by $0.03. The firm had revenue of $3.32 billion for the quarter, compared to the consensus estimate of $3.31 billion. Stryker had a return on equity of 26.93% and a net margin of 8.28%. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.53 EPS. On average, analysts expect Stryker to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.
Shares of Stryker stock opened at $167.76 on Tuesday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.15 and a current ratio of 1.83. The firm has a market cap of $63.18 billion, a price-to-earnings ratio of 25.85, a price-to-earnings-growth ratio of 2.37 and a beta of 0.59. Stryker has a 1-year low of $146.80 and a 1-year high of $179.84.
Several equities analysts have recently issued reports on the company. Citigroup lifted their price target on Stryker from $171.00 to $173.00 and gave the company a “neutral” rating in a research report on Wednesday, July 25th. BMO Capital Markets reiterated a “hold” rating and set a $174.00 price target on shares of Stryker in a research report on Thursday, July 12th. Robert W. Baird lifted their price target on Stryker from $187.00 to $192.00 and gave the company an “outperform” rating in a research report on Wednesday, July 25th. Canaccord Genuity reiterated a “buy” rating and set a $185.00 price target on shares of Stryker in a research report on Wednesday, July 25th. Finally, Royal Bank of Canada reiterated a “buy” rating and set a $184.00 price target on shares of Stryker in a research report on Wednesday, July 25th. Eight analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Stryker presently has a consensus rating of “Buy” and a consensus target price of $180.71.
In related news, VP Katherine Ann Owen sold 37,866 shares of Stryker stock in a transaction on Wednesday, September 5th. The stock was sold at an average price of $166.84, for a total value of $6,317,563.44. Following the transaction, the vice president now directly owns 11,367 shares in the company, valued at approximately $1,896,470.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Glenn S. Boehnlein sold 750 shares of Stryker stock in a transaction on Monday, October 1st. The stock was sold at an average price of $178.17, for a total value of $133,627.50. Following the completion of the transaction, the chief financial officer now owns 2,785 shares in the company, valued at $496,203.45. The disclosure for this sale can be found here. Insiders own 7.30% of the company’s stock.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Further Reading: How can you know how many shares are floating?
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.